- Report
- June 2023
- 227 Pages
Global
From €3373EUR$3,450USD£2,927GBP
- Clinical Trials
- June 2022
- 60 Pages
Global
From €1222EUR$1,250USD£1,061GBP
- Report
- January 2022
- 200 Pages
Global
From €7333EUR$7,500USD£6,364GBP
- Report
- January 2022
- 200 Pages
Global
From €7333EUR$7,500USD£6,364GBP
- Report
- January 2022
- 60 Pages
Global
From €3862EUR$3,950USD£3,352GBP
- Report
- January 2022
- 60 Pages
Global
From €3862EUR$3,950USD£3,352GBP
- Drug Pipelines
- January 2019
- 60 Pages
Global
From €1955EUR$2,000USD£1,697GBP
- Clinical Trials
- September 2020
- 237 Pages
Global
From €2444EUR$2,500USD£2,121GBP
- Drug Pipelines
- July 2020
- 36 Pages
Global
From €1955EUR$2,000USD£1,697GBP
- Drug Pipelines
- March 2021
Global
From €1955EUR$2,000USD£1,697GBP
- Report
- February 2023
- 40 Pages
Global
From €2053EUR$2,100USD£1,782GBP
- Report
- November 2021
- 70 Pages
Global
From €1950EUR$1,994USD£1,692GBP
- Report
- November 2021
- 70 Pages
Global
From €1950EUR$1,994USD£1,692GBP
- Report
- November 2021
- 70 Pages
Global
From €1950EUR$1,994USD£1,692GBP

Dyspepsia is a condition characterized by upper abdominal pain, bloating, and nausea. Dyspepsia drugs are used to treat the symptoms of dyspepsia, as well as other gastrointestinal disorders. These drugs are typically divided into two categories: antacids and proton pump inhibitors (PPIs). Antacids are used to neutralize stomach acid and reduce symptoms of heartburn and indigestion. PPIs are used to reduce the amount of acid produced in the stomach, which can help reduce symptoms of acid reflux and ulcers.
The dyspepsia drug market is a subset of the larger gastrointestinal drug market. This market is driven by the increasing prevalence of gastrointestinal disorders, such as irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer disease. Additionally, the rising demand for over-the-counter medications and the increasing availability of generic drugs are expected to drive the growth of the dyspepsia drug market.
Some companies in the dyspepsia drug market include Pfizer, GlaxoSmithKline, AstraZeneca, Merck, and Novartis. Show Less Read more